(Note: FBS Global Ltd. revived its IPO plans with a new F-1 filing on Dec. 5, 2024. Background: This filing followed the company’s withdrawal of its previous IPO plans in a letter to the SEC dated Nov. 4, 2024, stating that the company did not intend to pursue the IPO. FBS Global’s path to going […]

(Note: C&W Acquisition Corp. withdrew its SPAC IPO plans in an SEC filing dated Jan. 27, 2023. C&W Acquisition is a blank check company created by Cushman & Wakefield to search for target companies in real estate and PropTech (property technology). The S-1 was filed in March 2021. C&W Acquisition is incorporated in the Cayman […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTC Pink Market with the proposed NASDAQ symbol of “JETR” – a public offering of 2.88 million shares (2,875,000 shares) at the assumed offering price of $4.00. A 1-for-6 reverse stock split will take effect immediately after the effectiveness of this offering […]

Note: New Ruipeng Pet Group Inc. withdrew its plans for a U.S. IPO in a letter to the SEC dated June 6, 2024. The Chinese company had filed its F-1 on Jan. 23, 2023, but it had not disclosed terms. We are China’s largest one-stop pet care platform. We operate more than 1,900 pet hospitals […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the Tel Aviv Stock Exchange, where the stock’s last reported sale price was US$20.96 on Feb. 2, 2023, according to the prospectus. Enlight’s SEC filing calls the deal an “initial public offering” but it’s not; the stock already trades in Tel Aviv. IPOScoop […]

(Note: 5 Edge Acquisition Corp. withdrew its plans for its SPAC IPO in an SEC filing dated Jan. 18, 2023. The blank check company filed its S-1 in March 2021.) We  intend to focus our search for target companies on the telecom sector.  We intend to focus our search within the TMT sector (on areas) […]

Mineralys Therapeutics is a clinical biotechnology company developing a therapy for cardiorenal disease.  We are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are initially developing for the treatment of […]

Top KingWin offers financial advisory and other services to entrepreneurs and executives involved with small and medium-sized enterprises (SMEs) in China.  (Incorporated in the  Cayman Islands) We provide a number of important business services in China to young and emerging companies, including (i) corporate business training services, which mainly focus on advanced knowledge and new […]

Squarex Pharmaceutical Corp. is a Phase 2 biotech developing a therapy to prevent cold sores. We are a late-clinical-stage pharmaceutical company developing a drug that is intended to improve immune function to reduce severity and incidence of infectious disease with an initial focus on oral herpes. Our drug SQX770 has completed a Phase 1 and […]

(Note: Hesai Group is a holding company incorporated in the Cayman Islands. Hesai Group is offering the American Depositary Shares (ADS) in this IPO – and not the underlying business and its subsidiaries operating in mainland China. Each ADS will represent an undetermined number (at the present date of Jan. 17, 2023) of Class B […]